-
公开(公告)号：US20250011813A1
公开(公告)日：2025-01-09
申请号：US18774670
申请日：2024-07-16
Applicant: Cevec Pharmaceuticals, GmbH
Inventor： Kerstin Hein , Nicole Faust , Silke Wissing
Abstract: The present invention relates to host cells comprising a nucleic acid encoding Adeno-associated virus (AAV) Rep proteins Rep78 and Rep68, wherein the internal AAV promoter p19 has been inactivated by one or more mutations that maintain the functionality of said Rep78 and Rep68 proteins. The present invention further relates to respective nucleic acids and vectors comprising the same, as well as respective methods for the production of AAV.
-
公开(公告)号：US20150259387A1
公开(公告)日：2015-09-17
申请号：US14436125
申请日：2013-10-18
Applicant: CEVEC PHARMACEUTICALS GMBH
Inventor： Gudrun Schiedner , Bodo Plachter
IPC: C07K14/005 , G01N33/569 , C12N7/00
CPC classification number: C07K14/005 , A61K39/00 , C12N7/00 , C12N15/86 , C12N2710/16123 , C12N2710/16134 , C12N2710/16151 , G01N33/56994 , G01N2333/045 , G01N2469/20
Abstract: The present invention relates to a method for the production of human Cytomegalovirus (HCMV) particles, the method including the steps of: (a) contacting and thereby infecting a permanent human amniocyte cell with HCMV, (b) incubating the amniocyte cell, (c) allowing expression of HCMV particles, and (d) isolating of the HCMV particles, wherein the permanent human amniocyte cell expresses the adenoviral gene products E1A and E1B and wherein the amniocyte cells are cultured in serum free medium. Furthermore, the present invention relates to HCMV particles produced by the method of the present invention as well as to a HCMV based vaccine comprising the HCMV particles, the use of the HCMV particles for use in the preparation of a HCMV based vaccine and the HCMV particles for use in the preparation of a therapeutic or diagnostic agent for the prevention or treatment of a HCMV related disease.
Abstract translation: 本发明涉及一种生产人巨细胞病毒（HCMV）颗粒的方法，所述方法包括以下步骤：（a）使HCMV接触并由此感染永久性人类羊膜细胞，（b）孵育羊膜细胞，（c ），并且（d）分离HCMV颗粒，其中永久性人羊膜细胞表达腺病毒基因产物E1A和E1B，并且其中所述羊水细胞细胞在无血清培养基中培养。 此外，本发明涉及通过本发明的方法制备的HCMV颗粒以及包含HCMV颗粒的基于HCMV的疫苗，使用HCMV颗粒用于制备基于HCMV的疫苗和HCMV颗粒 用于制备用于预防或治疗HCMV相关疾病的治疗剂或诊断剂。
-
公开(公告)号：US20230348936A1
公开(公告)日：2023-11-02
申请号：US18301818
申请日：2023-04-17
Applicant: Cevec Pharmaceuticals, GmbH
Inventor： Kerstin Hein , Nicole Faust , Silke Wissing
CPC classification number: C12N15/86 , C12N15/01 , C12N15/63 , C12N2750/14152 , C12N2750/14122 , C12N2750/14143
Abstract: The present invention relates to host cells comprising a nucleic acid encoding Adeno-associated virus (AAV) Rep proteins Rep78 and Rep68, wherein the internal AAV promoter p19 has been inactivated by one or more mutations that maintain the functionality of said Rep78 and Rep68 proteins. The present invention further relates to respective nucleic acids and vectors comprising the same, as well as respective methods for the production of AAV.
-
公开(公告)号：US10793839B2
公开(公告)日：2020-10-06
申请号：US16107009
申请日：2018-08-21
Applicant: Cevec Pharmaceuticals GmbH
Inventor： Silke Wissing , Jens Wölfel , Nicole Faust
IPC: C12N9/10 , C12P21/00 , C07K14/475 , C07K14/81
Abstract: The present invention relates to cell lines that are genetically modified to overexpress a β-galactoside α-2,3-sialyltransferase 1 (ST3Gal1), preferably human ST3Gal1, which can be used for the production of recombinant glycoproteins having highly or fully sialylated O-linked GalNAc glycans (GalNAc O-glycans), preferably core 1 GalNAc O-glycans, as well as to respective recombinant glycoproteins. Further, the present invention relates to respective methods of expressing recombinant glycoproteins, methods of increasing the degree of sialylation of recombinant glycoproteins, and methods of decreasing the micro-heterogeneity of GalNAc O-glycans. Finally, the present invention relates to respective uses of the above cell lines for the production of recombinant glycoproteins, for increasing the degree of sialylation of recombinant glycoproteins, and for decreasing the micro-heterogeneity of O-linked GalNAc glycans of recombinant glycoproteins.
-
公开(公告)号：US12060569B2
公开(公告)日：2024-08-13
申请号：US18301818
申请日：2023-04-17
Applicant: Cevec Pharmaceuticals, GmbH
Inventor： Kerstin Hein , Nicole Faust , Silke Wissing
CPC classification number: C12N15/86 , C12N15/01 , C12N15/63 , C12N2750/14122 , C12N2750/14143 , C12N2750/14152
Abstract: The present invention relates to host cells comprising a nucleic acid encoding Adeno-associated virus (AAV) Rep proteins Rep78 and Rep68, wherein the internal AAV promoter p19 has been inactivated by one or more mutations that maintain the functionality of said Rep78 and Rep68 proteins. The present invention further relates to respective nucleic acids and vectors comprising the same, as well as respective methods for the production of AAV.
-
Patent Agency Ranking
公开(公告)号：US12060561B2
公开(公告)日：2024-08-13
申请号：US16636622
申请日：2018-08-01
Applicant: CEVEC Pharmaceuticals GmbH
Inventor： Nicole Faust , Silke Wissing , Nikola Strempel
IPC: C07K14/705 , C07K14/71 , C07K19/00 , C12N5/07 , C12N5/071 , C12N5/10 , C12N5/16 , C12N15/09 , C12N15/113 , C12N15/62 , C12N15/63 , C12N15/85
CPC classification number: C12N15/62 , C07K14/70517 , C07K14/71 , C07K19/00 , C12N5/06 , C12N5/0625 , C12N5/10 , C12N5/16 , C12N15/09 , C12N15/1138 , C12N15/63 , C12N15/85 , C07K2319/00 , C12N2501/105
Abstract: The present invention relates to methods for the selection of a stable producer cell line expressing one or more protein(s) of interest (POIs), comprising the stable transfection of cells with a gene encoding a constitutively active variant of a growth factor receptor, respective methods for the expression of one or more POIs in such stable producer cell lines, and uses of a constitutively active variant of a growth factor receptor as selection marker in the cultivation of cells.
-
公开(公告)号：US20200095562A1
公开(公告)日：2020-03-26
申请号：US16107009
申请日：2018-08-21
Applicant: Cevec Pharmaceuticals GmbH
Inventor： Silke Wissing , Jens Wölfel , Nicole Faust
IPC: C12N9/10 , C12P21/00 , C07K14/475 , C07K14/81
Abstract: The present invention relates to cell lines that are genetically modified to overexpress a β-galactoside α-2,3-sialyltransferase 1 (ST3Gal1), preferably human ST3Gal1, which can be used for the production of recombinant glycoproteins having highly or fully sialylated O-linked GalNAc glycans (GalNAc O-glycans), preferably core 1 GalNAc O-glycans, as well as to respective recombinant glycoproteins. Further, the present invention relates to respective methods of expressing recombinant glycoproteins, methods of increasing the degree of sialylation of recombinant glycoproteins, and methods of decreasing the micro-heterogeneity of GalNAc O-glycans. Finally, the present invention relates to respective uses of the above cell lines for the production of recombinant glycoproteins, for increasing the degree of sialylation of recombinant glycoproteins, and for decreasing the micro-heterogeneity of O-linked GalNAc glycans of recombinant glycoproteins.
-
公开(公告)号：US20240263148A1
公开(公告)日：2024-08-08
申请号：US18005027
申请日：2021-11-23
Applicant: Cevec Pharmaceuticals GmbH
Inventor： Juliana Coronel , Silke Wissing
CPC classification number: C12N7/00 , C12M29/10 , C12N15/86 , C12N2750/14122 , C12N2750/14143 , C12N2750/14152
Abstract: The present invention relates to methods for the production of Adeno-associated virus (AAV), comprising steps of providing a stable AAV producer cell line in which at least some or all genes encoding the components necessary for the production of AAV are stably integrated into the cell genome, and culturing said cells in perfusion culture during the AAV production step (i.e., during the N step), wherein said perfusion culture encompasses continuous replacement of spent media with fresh media, and wherein said continuous replacement of spent media with fresh media continues after the induction of AAV production.
-
公开(公告)号：US20200377895A1
公开(公告)日：2020-12-03
申请号：US16636622
申请日：2018-08-01
Applicant: CEVEC Pharmaceuticals GmbH
Inventor： Nicole Faust , Silke Wissing , Nikola Strempel
Abstract: The present invention relates to methods for the selection of a stable producer cell line expressing one or more protein(s) of interest (POIs), comprising the stable transfection of cells with a gene encoding a constitutively active variant of a growth factor receptor, respective methods for the expression of one or more POIs in such stable producer cell lines, and uses of a constitutively active variant of a growth factor receptor as selection marker in the cultivation of cells.
-
公开(公告)号：US20200277628A1
公开(公告)日：2020-09-03
申请号：US16646741
申请日：2018-09-18
Applicant: Cevec Pharmaceuticals, GmbH
Inventor： Kerstin Hein , Nicole Faust , Silke Wissing
IPC: C12N15/86
Abstract: The present invention relates to host cells comprising a nucleic acid encoding Adeno-associated virus (AAV) Rep proteins Rep78 and Rep68, wherein the internal AAV promoter p19 has been inactivated by one or more mutations that maintain the functionality of said Rep78 and Rep68 proteins. The present invention further relates to respective nucleic acids and vectors comprising the same, as well as respective methods for the production of AAV.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.014 seconds)
